Related Experiment Video

Updated: Jul 18, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents

J Roig1, J Casal, P Gispert

  • 1Pulmonary Division, Hospital Nostra Senyora de Meritxell, 1-13 Fiter Rossell, Escaldes, Andorra AD700. averoig@mypic.ad

Medecine Et Maladies Infectieuses
|November 11, 2006
PubMed

Insights

Certain antibiotics effectively treat community-acquired pneumonia (CAP) caused by intracellular pathogens. Azithromycin is recommended for antibiotic prophylaxis in specific situations due to its favorable pharmacokinetic profile.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Respiratory Medicine

Background:

  • Community-acquired pneumonia (CAP) can be caused by intracellular pathogens like Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp.
  • Macrolides, fluoroquinolones, doxycycline, and ketolides exhibit intrinsic activity against these pathogens.

Purpose of the Study:

  • To review the efficacy of various antibiotic classes against common intracellular pathogens causing CAP.
  • To compare the pharmacokinetic profiles and clinical utility of macrolides and fluoroquinolones.
  • To evaluate the role of azithromycin in antibiotic prophylaxis for specific epidemiological settings.

Main Methods:

  • Literature review of studies investigating antibiotic activity against intracellular pneumonia pathogens.
  • Comparative analysis of pharmacokinetic and pharmacodynamic properties of macrolides and fluoroquinolones.
  • Assessment of clinical outcomes and prophylactic use of azithromycin in outbreaks.

Main Results:

  • Macrolides, fluoroquinolones, doxycycline, and ketolides are effective against M. pneumoniae, C. pneumoniae, and Legionella spp.
  • Newer fluoroquinolones (gemifloxacin, moxifloxacin) and macrolides (azithromycin, clarithromycin) show improved activity and pharmacokinetics.
  • Azithromycin demonstrates efficacy in antibiotic prophylaxis for M. pneumoniae outbreaks due to its pharmacokinetic advantages.

Conclusions:

  • Antibiotics like macrolides and fluoroquinolones are crucial for treating CAP caused by intracellular pathogens.
  • Azithromycin is a preferred agent for prophylaxis in certain settings, particularly for Mycoplasma pneumoniae outbreaks.
  • While pathogen shedding may persist post-therapy, clinical outcomes are generally favorable.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...